Shao Lee Lin Horizon Therapeutics Public LTD CO (HZNP) insider trading activity

Shao Lee Lin is EVP, Head of R&D and CSO of Horizon Therapeutics Public Ltd Co. Currently has a direct ownership of 109,668 shares of HZNP, which is worth approximately $0. The most recent transaction as insider was on Jan 21, 2020, when has been sold 2,716 shares (Ordinary Shares) at a price of $38.25 per share, resulting in proceeds of $103,887. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 110K

0% 3M change

0% 12M change

Total Value Held $0

Shao-Lee Lin Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 21 2020	SELL Payment of exercise price or tax liability	$103,887 $38.25 p/Share	2,716 Reduced 2.42%	109,668 Ordinary Shares
Jan 21 2020	BUY Grant, award, or other acquisition	-	6,129 Added 5.17%	112,384 Ordinary Shares
Jan 05 2020	SELL Payment of exercise price or tax liability	$1,375,410 $36.1 p/Share	38,100 Reduced 26.39%	106,255 Ordinary Shares
Jan 05 2020	BUY Grant, award, or other acquisition	-	35,652 Added 19.81%	144,355 Ordinary Shares
Jan 05 2020	BUY Exercise of conversion of derivative security	-	50,344 Added 31.65%	108,703 Ordinary Shares
Jan 04 2020	SELL Payment of exercise price or tax liability	$292,879 $36.1 p/Share	8,113 Reduced 12.21%	58,359 Ordinary Shares
Jan 04 2020	BUY Exercise of conversion of derivative security	-	17,892 Added 21.21%	66,472 Ordinary Shares

Feb 20 2019	SELL Payment of exercise price or tax liability	$340,224 $21.54 p/Share	15,795 Reduced 24.94%	47,531 Ordinary Shares
Feb 20 2019	BUY Grant, award, or other acquisition	-	35,652 Added 36.02%	63,326 Ordinary Shares
Jan 05 2019	SELL Payment of exercise price or tax liability	$292,331 $20.39 p/Share	14,337 Reduced 34.13%	27,674 Ordinary Shares
Jan 05 2019	BUY Exercise of conversion of derivative security	-	32,362 Added 43.51%	42,011 Ordinary Shares
Jan 04 2019	SELL Payment of exercise price or tax liability	$168,054 $20.39 p/Share	8,242 Reduced 46.07%	9,649 Ordinary Shares
Jan 04 2019	BUY Exercise of conversion of derivative security	-	17,891 Added 50.0%	17,891 Ordinary Shares

Also insider at

SRZN

Surrozen, Inc. Healthcare

THRD

Third Harmonic Bio, Inc. Healthcare

Director

SLRN

ACELYRIN, Inc.

Chief Executive Officer

Shao Lee Lin

EVP, Head of R&D and CSO

Dublin, L2

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells HZNP shares.

Notify only if

Value

Insider Trading

Get notified when an Horizon Therapeutics Public LTD CO insider buys or sells HZNP shares.

Notify only if

Operation

Value

Type

News

Receive news related to Horizon Therapeutics Public Ltd Co

Track Activities on HZNP

Account